Brain-derived neurotrophic factor (BDNF) is a nerve growth factor that has antidepressant-like effects in animals and may be implicated in the etiology of mood-related phenotypes. However, genetic association studies of the BDNF Val66Met polymorphism (single nucleotide polymorphism rs6265) in major depressive disorder (MDD) have produced inconsistent results. We conducted a meta-analysis of studies comparing the frequency of the BDNF Val66Met-coding variant in depressed cases (MDD) and nondepressed controls. A total of 14 studies involving 2812 cases with DSM-III or -IV defined MDD and 10 843 nondepressed controls met the inclusion criteria. Analyses were stratified either by gender or ethnicity (Asian and Caucasian) because MDD is more prevalent in women and in Caucasians and because BDNF allele frequencies differ by ethnicity. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were provided for allelic analyses (Met versus Val), as well as for genotypic analyses (Met/Met and Val/Met versus Val/Val). In the total sample, the BDNF Val66Met polymorphism was not significantly associated with depression. However, the gender stratified analyses revealed significant effects in both the allelic and genotypic analyses in men (OR MET , 95% CI; 1.27 (1.10-1.47); OR MET/MET , 95% CI; 1.67 (1.19-2.36)). Stratification according to ethnicity did not show significant effects of the Val66Met polymorphism on MDD. Our results suggest that the BDNF Val66Met polymorphism is of greater importance in the development of MDD in men than in women. Future research into gender issues will be of interest.
Introduction
Major depressive disorder (MDD) is one of the most common psychiatric disorders and causes impairment in several aspects of life. MDD is a multifactorial disorder with multiple genetic and nongenetic factors contributing to the disorder with a relatively small effect. 1 Twin studies estimate the heritability of MDD to be moderate, in the range of 35-40%. 2, 3 Several candidate genes have been described for MDD, 4 ,5 one of which is the gene encoding the brain-derived neurotrophic factor (BDNF), located on chromosome 11p13. 6 The BDNF gene codes for a neurotrophin that is highly expressed in the central nervous system, especially in the hippocampus. 7, 8 BDNF plays a role in the proliferation, differentiation and survival of neuronal cells, [9] [10] [11] and regulates synaptic plasticity and connectivity in the adult brain. 9, 12 According to the 'neurotrophic hypothesis' of depression, 10 a reduction in BDNF expression is involved in the pathophysiology of MDD, [10] [11] [12] [13] [14] whereas the use of antidepressants leads to an upregulation of BDNF in the hippocampus of subjects with MDD. 10, 12, 15, 16 A single nucleotide polymorphism (rs6265) in exon 11 of the BDNF gene results in an amino-acid substitution from valine to methionine at codon 66 (Val66-Met) in the prodomain of BDNF.
11 Val66Met is a common polymorphism with allele frequencies that are dependent on ethnic background. In Caucasian populations, the frequency of the Met allele is 25-32%, 17, 18 whereas in Asian populations the Met allele is more frequent, around 40-50%. [19] [20] [21] Currently, it is still unclear what the consequences of the Val66Met polymorphism are on brain function, as both alleles have been associated with different disease processes including substance-related disorders, schizophrenia, and eating disorders. 22 The risk allele for depression and depression-related traits has also not been clearly defined. A number of studies have suggested that the Met allele is associated with poorer episodic memory performance, 23, 24 a symptom often observed in subjects with MDD. 25 Furthermore, it has been shown that the Met allele is associated with reduced hippocampal activity. 23, 26 Studies in in vitro and in animal models have shown that the presence of the Met allele alters the sorting and secretion of proBDNF, such that less regulated (activity dependent) secretion is likely to occur in carriers of at least one Met allele. This is reflected in reduced hippocampal synaptic activity. Those individuals may, however, have more constitutively secreted BDNF. 23, 24, 27 In contrast, the Val allele has been found associated with higher trait anxiety and higher mean neuroticism scores, 14, 28 which are potent risk factors for the development of depression. 29, 30 Also, a family-based study showed the Val allele to be associated with childhood-onset mood disorders. 31 Other studies did not observe any association of the Val66Met polymorphism with MDD 11, [32] [33] [34] (see also Table 1 ).
The inconsistencies in association studies of the BDNF Val66Met polymorphism with mood disorders might also result from the lack of statistical power in studies of small sample size and from variation across studies in inclusion criteria, such as the definition of psychiatric phenotype, or ethnicity. For example, some studies used broad criteria in which individuals with MDD, bipolar disorders, and dysthymia were included, 41, [44] [45] [46] [47] whereas others included individuals with MDD only. 11, 33, 35, 42 There are two other issues in MDD that might contribute to the inconsistency of association findings. The first is the gender difference in MDD prevalence and gender-related differences in the etiology of MDD. 48 Two large population-based studies, the National Comorbidity Survey-Replication (NCS-R; 9892 inhabitants of the United States 49 ) and the Netherlands Mental Health Survey and Incidence Study (NEMESIS; 7076 Dutch adults 50 ), have shown a gender difference in the lifetime prevalence of MDD of 20.1-21.3% in women and 10.9-12.7% in men. [50] [51] [52] In Asian populations, the female/male ratio is also around 2:1. 53 Some studies have reported a significantly higher heritability of MDD in women (40-42%) than in men (29-31%), [54] [55] [56] whereas others did not observe gender differences in heritability. 3, 57, 58 Furthermore, genetic linkage studies in families with recurrent, early-onset MDD showed significant log of the odds scores for multiple loci of which some regions were only observed among female affected relative pairs and not among males. [59] [60] [61] This might indicate that sex-specific susceptibility genes contribute to the development of MDD.
The second issue is the difference in lifetime prevalence rates of MDD between Western and Asian countries. Lower lifetime prevalence of MDD has been observed in Chinese, Japanese and Korean populations. 62, 63 Cross-national epidemiologic surveys indicated that the lifetime prevalence of MDD is 1.5% in Taiwanese and 2.9% in Koreans, 53 compared to a mean of 15-17% in Western populations. 50, 52, 64 Although a number of the studies mentioned above have suggested the Met allele to be the risk allele for depression, the higher frequency of the Met allele in Asians in the presence of lower MDD prevalence rates might suggest that the Met allele protects against MDD.
The aim of the current study was to perform a metaanalysis (see Munafo and Flint, 65 Trikalinos et al.
66
) of all available case-control association studies of the BDNF Val66Met polymorphism in adults and elderly with current MDD or MDD within 1 year before study inclusion. We examined the roles of gender and ethnicity as potential modifiers of the relationship between the Val66Met polymorphism of BDNF and MDD, because (1) MDD is more prevalent in women than men, (2) the lifetime prevalence of MDD differs between Caucasians and Asians and (3) the frequency of the BDNF Val66Met polymorphism is dependent on ethnic origin.
Materials and methods

Search strategy
Studies were identified through Medline, PubMed, EmBase and PsychINFO using the search terms (1) Val66Met and (depress* or mood disorde* or major depress*), and (2) rs6265 and (depress* or mood disorde* or major depress*). Studies published in the English language before the 1st of January 2008 were considered. We searched the reference lists of studies included to identify other potentially eligible studies.
Inclusion criteria
Case-control studies reporting genotype or allele frequencies of the BDNF Val66Met polymorphism in depressed cases (MDD) and in (nondepressed) controls were eligible for inclusion in this meta-analysis. Case status was defined as having a current or one-year DSM-III-, DSM-IIIR-, or DSM-IV-(Diagnostic and Statistical Manual of Mental Disorders) based diagnosis of MDD assessed by established psychiatric interviews. Studies of any ethnic group were included as were several age categories (adults, elderly and geriatric subjects). For inclusion of a study, we required genotype frequencies to be in Hardy-Weinberg equilibrium (HWE) in the healthy controls (P > 0.01).
Case-only studies, family-based designs and population studies with healthy subjects were excluded, as were studies describing effects of BDNF on depression-related phenotypes such as anxiety or personality traits.
In most studies, control subjects had been screened for the presence of psychopathology. In a minority of the studies this was not reported. 36, 39, 42 This was not an exclusion criterion.
The methods used for genotyping in the different reports included restriction fragment length polymorphism analysis, 19 38 and an Illumina Beadarray-based analysis. 39 
Data extraction
Two investigators (MV, AvdM) performed the literature search and reviewed the results, independently. Full articles were retrieved for further assessment if the information in the title or abstract suggested that the study: (1) compared depressed subjects (MDD) with healthy controls; and (2) assessed the BDNFcoding variant Val66Met (rs6265). Studies that were not available on the Internet or via libraries were obtained by contacting the authors. 41, 67, 68 We obtained all requested data.
Data from each study were extracted independently by three investigators (MV, AvdM, PvD), using a standardized data extraction form. In case of disagreement of study inclusion, a fourth investigator was involved (JJ). In case more psychiatric diagnoses were described in one study, only data from the MDD samples were extracted. If essential data were missing from the study reports, the authors of the respective papers were contacted and asked to provide additional data. This was successful in all cases.
The following data were coded: author(s) and year of publication, methods (study design, sample sizes for both cases and controls, diagnostic tools for determination of case status, definition of case status) and sample characteristics (gender ratio, mean age, ethnic background, HWE in controls, genotype and allele frequencies). Ethnic origin was either Caucasian or Asian.
In addition, we contacted all authors by email to obtain gender-specific data such as mean age, and genotype and allele frequencies per gender, which most of them made readily available to us. 11, 19, 21, 33, 34, 36, 37, 40, 42, 43 Statistical analysis The meta-analysis examined the allelic association of the Met allele with the risk of MDD relative to the Val allele (OR Met versus Val). Besides this, genotypic ORs were calculated for the heterozygous Val/Met and homozygous Met/Met genotypes separately, with the Val/Val genotype as the reference. Allele frequencies and genotype distribution were extracted for cases and controls. For some studies, allele frequencies were calculated from the available data. Zero cell correction 69, 70 was applied in the studies where cells from the crosstabulations contained zeros. 35, 36, 38, 40 This correction is necessary to obtain ORs from every crosstabulation. The distribution of genotypes in the control group was tested for HWE in each paper using an exact test. 71 To combine the individual study results, we conducted meta-analyses using RevMan (version 4.2 72, 73 ). The heterogeneity between studies was tested using the Q-statistic, which is a weighted sum of the squares of the deviations of individual study OR estimates from the overall estimate. When the ORs are homogeneous, Q follows a w 2 distribution with r-1 (r is the number of studies) degrees of freedom (d.f.). If P Q < 0.10, the heterogeneity was considered to be statistically significant. 74, 75 Inconsistency across studies was quantified with the I 2 metric (I 2 = QÀd.f./Q), which can be interpreted as the percentage of total variation across several studies due to heterogeneity. I 2 takes values between 0 and 100%, with higher values denoting a greater degree of heterogeneity (0-25%: no heterogeneity; 25-50%: moderate heterogeneity; 50-75%: large heterogeneity and 75-100%: extreme heterogeneity). 76 When no heterogeneity was present, the pooled OR was estimated using fixed effects models. 77, 78 Otherwise, random effects models 79 were applied to obtain the pooled OR. Random effects modeling assumes a genuine diversity in the results of various studies and it incorporates a between-study variance into the calculations. 80 The results of the association tests are indicated as pooled ORs with the corresponding 95% confidence intervals of the Val66Met-induced risk of MDD. P < 0.05 was considered statistically significant.
A random effects meta-regression of effect size with mean age and the proportion of women as covariates was performed with use of R 2.7.0 81 to determine whether these covariates influenced effect size. Studies were weighted, so that the more precise studies had more influence in the regression analyses.
The STATA statistical software package 82 was used to detect the presence of potential publication bias. A differential magnitude of effect in large versus small studies for the genetic contrasts under investigation was checked using the Egger regression test for funnel plot asymmetry 83 and the Begg-Mazumdar test, which is based on Kendall's-t. 84 They were considered statistically significant at P < 0.10.
The meta-analysis consisted of two steps: (1) the overall analysis, which included all available data, and (2) subgroup analyses by ethnicity and gender. In addition, we performed sensitivity analyses and meta-regression analyses. In total, five different samples (total sample, men only, women only, Asians only, Caucasians only) were analyzed for both allelic and genotypic contrasts.
Results
The literature search yielded 42 studies. We excluded 28 studies for reasons specified in Figure 1 and included 14 studies with 16 samples in the metaanalysis (Table 1 and Figure 1 ). In total, 12 authors provided additional data for the gender-specific analyses in 12 samples (Figure 1) .
Overall, the studies provided 2812 cases (57.4% women, mean age 50.6 years) and 10 843 controls (51.2% women, mean age 47.6 years; Table 1 ). Genotype distributions and allele frequencies are shown in Table  2 . The Val allele was most common in both cases and controls and was significantly higher in the Caucasian pooled sample (t = 11.37, d.f. = 14, P < 0.001).
In the majority of our meta-analytic tests, no significant heterogeneity was observed (Table 3) . No evidence of potential publication bias was found (results not shown).
Association of BDNF
The analysis of the allelic association of the Met allele with the risk of MDD revealed significant heterogeneity between the 16 samples. The random effects pooled OR was not significant (Table 3 ). For the genotypic analyses (the Met/Met and Val/Met genotype relative to the Val/Val genotype), no evidence of heterogeneity was found. Therefore, fixed effects models were applied; the genotypic pooled ORs were not significant, either.
BDNF Val66Met, MDD and gender
The subgroup analyses based on stratification by gender showed significant effects of BDNF on MDD in men (Table 3 and Figure 2a ; males). When comparing male MDD cases with male controls for the increase in risk of MDD due to BDNF alleles, male MDD cases carried the Met allele significantly more often (P = 0.001; 32.5% in MDD cases versus 22.2% in controls). For the Met/Met genotype, the same pattern emerged (P = 0.003; 21.9% in MDD cases versus 7.9% in controls; Figure 2b ; males). After correcting for multiple testing with use of the Bonferroni method (P = 0.0033), these results remained significant. The Val/Met genotype did not show an association with MDD in men. For women no differences between cases and controls were observed for the BDNF polymorphism (Table 3) .
BDNF Val66Met, MDD and ethnicity
In the subgroups stratified by ethnicity (Caucasian or Asian), neither the allele-based analysis nor the genotype-based analyses showed significant effects of the Val66Met polymorphism on MDD risk.
Sensitivity analyses
Sensitivity analyses were performed excluding studies that did not report on the screening for the presence of psychopathology in control subjects. 36, 39, 42 Excluding these studies did not substantially alter the ORs as reported above. A sensitivity analysis was also performed with the inclusion of a study 106 with genotype frequencies deviating from HWE. 106 The reported ORs hardly changed (data not shown).
Meta-regression analyses
Results of the meta-regression analyses showed that mean age significantly influenced the variation in effect size in the Met/Met analyses (P = 0.009) and in the allelic analyses (P = 0.01), with elderly subjects Figure 1 Study selection for the meta-analysis. Excluded: no MDD phenotype, 8, 14, 67, 68, [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] no case-control design, 22, 31, [98] [99] [100] [101] [102] [103] no adults 104, 105 and no Hardy-Weinberg equilibrium (HWE). 106 Included: Caucasian studies, 11, [33] [34] [35] [36] [37] [38] [39] [40] Asian studies 19, 21, [41] [42] [43] and gender studies. 11, 19, 21, [34] [35] [36] [37] [38] [40] [41] [42] [43] showing higher ORs. The effect of gender was also in the expected direction, though this result did not reach statistical significance (data not shown).
Discussion
This meta-analysis of the association of the BDNF Val66Met polymorphism with MDD investigated 2812 patients and 10 843 controls from 14 case-control studies. Our overall meta-analysis did not detect any significant genetic association between the BDNF Val66Met polymorphism and MDD. This result is in line with that of three other previously published meta-analyses that had included fewer studies of the BDNF Val66Met polymorphism and MDD. 5, 22, 107 As far as we know, this is the largest meta-analysis carried out so far aimed at investigating the relationship between BDNF and MDD. Also, our metaanalysis is the first one to take gender and ethnicity into account. This was done given earlier evidence of women being affected with MDD two times as often as men 53 and the Met allele frequency being higher in Asians in the presence of lower MDD prevalence rates compared to Caucasians. The exploration of gender specificity indeed revealed significant allelic (Met versus Val) and genotypic (Met/Met versus Val/Val) associations of BDNF with MDD in the male gender. We will discuss these findings in more depth below, but like to note here that the results of genetic association studies of the BDNF Val66Met polymorphism with different psychiatric phenotypes have shown to be complex. 22 As illustrated in a recent meta-analysis of Gratacos et al., 22 the Val/Met and Met/Met genotypes were found to increase the risk of eating disorders and schizophrenia, although reducing the risk of substance-related disorders.
There is no straightforward explanation for the Met allele increasing MDD risk for men, but not women, in both allelic and genotypic analyses as the allele and genotype frequencies of Val66Met are equally distributed among both genders. Further, as no gender differences have been reported in the levels of serum or plasma BDNF, 13, 108, 109 simple biochemical explanations are unlikely.
How could the BDNF gene influence MDD development in a gender-specific way? Probable explanations can be sought when we consider that the total constellation of causal factors, that is the interplay between genetic and environmental factors, may in essence differ for men and women. As outlined above, genetic linkage studies have identified gender-specific MDD-linked regions of the genome; a 451 kb region of 2q33-35 for example, exhibited significant evidence of linkage to MDD among women, but not men, 60 and a follow-up study identified CREB1 as a gender-limited susceptibility gene for MDD. 110 In this context, it might merit further research whether gender-related epistatic effects exist, in which gene-gene interactions involving the Val66Met polymorphism and leading to MDD are different in men compared to women. (10) Abbreviations: OR, odds ratio; CI, confidence interval; Met, methionine; Val, valine. *P < 0.05, **P < 0.01.
Four other possible explanations may be sought at the level of gender differences in gene-environment interaction, of sexual dimorphism of the hippocampus, of gender-related differences in symptoms of depression and of a type I error finding. First, interactions between the BDNF Val66Met polymorphism and environmental influences may differ between men and women. Life events are part of the etiologic constellation of MDD and are found to be associated with the development of depression. [111] [112] [113] Although the amount of life events men and women experience is rather similar, several studies conclude that women subjectively experience more stress, have an increased stress response 114 and show higher stress vulnerability in relation to life events and chronic difficulties. 115, 116 Interactions between a candidate gene for depression, the serotonin transporter polymorphism (5-HTTLPR), and life events have been described as etiologic factors for MDD. 106, [117] [118] [119] Some reports have indicated that the interaction between this polymorphism and life events differs with gender. 120, 121 Adolescent girls with the short allele of the 5-HTTLPR displayed more depression when they had experienced adverse events, whereas in boys, adverse events in interaction with the long allele led to higher depression scores. 120 This opposite finding in girls and boys may be due to the gender-specific influence of gonadal or adrenocortical hormones interacting with the 5-HTTLPR polymorphism. 120 In a similar way, gender-specific mechanisms could also operate for the BDNF Val66Met polymorphism and life events.
Second, the gender-related influence of the BDNF Val66Met polymorphism in depression may be due to sexual dimorphism in brain structures involved in the neurobiology of depression, particularly, the hippocampus. 122 Male and female hippocampi have been documented to differ significantly in their anatomical structure, their neurochemical make-up and their reactivity to stressful situations. 122, 123 Imaging studies consistently show that the hippocampus is larger in women than in men when adjusted for total brain size. 124 Biochemical studies have revealed sex differences in many neurotransmitter systems within the hippocampus, including the adrenergic, serotonergic, cholinergic and corticosterone systems. 123 An intriguing but relatively unknown hippocampal sex difference is the reaction to chronic stress. In both rats and monkeys, chronic stress causes damage to the hippocampus in men, but does so far less, if at all, in women. 125 Stress leads to decreased levels of BDNF expression in the hippocampus, 126 and upregulation of BDNF is associated with the therapeutic effects of antidepressant medication and electroconvulsive shock treatment in depression. 15 As the BDNF gene plays a role in survival of neuronal cells, in connectivity, and in plasticity, a more efficiently expressing BDNF allele might protect the brain against hippocampal damage after stress, or at least might render an individual less vulnerable to the effects of sustained stress and thus, less vulnerable to MDD. Given these findings, the BDNF Val66Met polymorphism may play a larger role in the neurobiological underpinnings of depression in men than in women.
Third, depression at the symptomatic level is characterized by both symptoms of behavioral despair, such as negative mood, hopelessness, agitation and suicidal ideation, and by an inability to experience pleasure (anhedonia). These different sets of symptoms appear to be related to two distinct brain systems, the hippocampus-HPA stress system, and the dopaminergic brain reward systems in the ventral tegmentum area and the nucleus accumbens. 7 In this context, it is relevant that BDNF seems to exert opposing effects on these two systems, with the result that infusion of BDNF in the hippocampus produces antidepressant effects, 127, 128 and application of BDNF in the ventral tegmentum area and the nucleus accumbens leads to prodepressive effects. 129 Gender differences in symptomatic expression of depression and gender differences in the involvement of brain stress and reward systems could explain genderdependent effects of the BDNF Val66Met polymorphism in depression.
Fourth, as a substantial number of tests was performed, one could argue that the gender-specific finding actually is a type I error finding. However, after applying the Bonferroni method to correct for multiple testing, the gender-specific finding remained significant, both in the genotypic and allelic analyses.
The results of our meta-analysis do not support a clear role for ethnicity in relation to the BDNF Val66Met polymorphism and MDD risk. The lower prevalence of MDD in Asians compared to Caucasians in the presence of higher Met allele frequencies in Asians may suggest the Met allele to be protective against MDD in Asian subjects. However, in the ethnicity-specific analyses this was not observed. The lower prevalence of MDD in Asians might partly be accounted for by underreporting due to cultural reluctance to endorse symptoms, by depressive symptoms being expressed as somatic symptoms, by greater resilience, by availability of more social support in Asian societies or by higher tolerance of symptoms and disease. 53, 62, 63, 130 It is remarkable that the studies carried out in the eldest age groups appeared to have the highest ORs for the association of the BDNF Val66Met polymorphism with MDD ( Figures 2a and b: Hwang et al. 42 and Taylor et al.
40
). Both samples had late-onset depression (mean age of 68.4 and 45.0 years, respectively). This age effect has also been noted in the metaanalysis by Chen et al. 107 Samples with late-onset or geriatric depression are etiologically different from adult-onset depression with a larger role of cardiovascular risk factors 131 and a stronger involvement of the hippocampus, which is the major site of BDNF expression. 42, 132 From the meta-regression analysis with mean age as covariate it appeared that age might modify the relationship between the Met allele and depression. However, firm conclusions cannot be drawn and cautiousness about an age effect is required, the more since a haplotype containing the BDNF Val allele was found to be associated with childhood-onset MDD in two independent samples using a family-controlled design. 31 This subject needs to be explored in future studies.
This meta-analysis should be viewed in the context of its strengths and limitations. An obvious strength is that this is the largest sample studied in a metaanalysis to date and that stratified analyses were performed for gender and ethnicity. The inferences from this meta-analysis are necessarily limited by the quality and quantity of the available case-control studies on the association of the BDNF Val66Met polymorphism and MDD. In particular, the reports available covered a wide-age range, which could imply that different age of onset groups were included. Furthermore, a breakdown of the results according to gender proved to be impossible in a subsample of studies. Lastly, MDD seldom presents as a single disorder 49 but information about the presence of comorbid psychiatric conditions in the subjects was not available to us. Thus, this meta-analysis reports on the association of the BDNF Val66Met polymorphism and MDD without taking into account the possible effect of comorbid disorders.
In conclusion, our results suggest that the BDNF Val66Met polymorphism is of greater importance in the development of MDD in men than in women. However, a larger primary study will be necessary to confirm or refute this. Power analysis for such a study revealed that to detect a significant allelic association (Met versus Val) with 80% power at the 5% significance level (ORX1.27), at least 870 and 1300 male case-control pairs are required, in Asians and Caucasians, respectively. Our study provides clues for further research, such as the exploration of differences in genetic risk factors and gene-environment interaction constellations between men and women and the study of gender issues in MDD.
